Literature DB >> 19604177

Ascites improves upon [corrected] serum sodium plus [corrected] model for end-stage liver disease (MELD) for predicting mortality in patients with advanced liver disease.

M Somsouk1, J Guy, S W Biggins, E Vittinghoff, M A Kohn, J M Inadomi.   

Abstract

BACKGROUND: The clinical impact of ascites has historically been well recognized; however, its value is unclear in the context of current prognostic models. AIM: To determine whether ascites can improve risk discrimination beyond model for end-stage liver disease (MELD) and serum sodium (MELDNa).
METHODS: Consecutive cirrhotic patients were evaluated for ascites on the basis of an outpatient CT along with concurrent MELD and Na values. Cox models were used to determine the added value of ascites for predicting 1-year mortality. Increases in the C-index, integrated discrimination improvement (IDI) and the net reclassification index (NRI) were used to assess improvements in discrimination after the addition of ascites.
RESULTS: A total of 1003 patients had Na and MELD scores available within 30 days of the CT scan. A total of 60 deaths occurred within 1 year, with mortality higher in patients with ascites (21.4% vs. 4.0%, HR 6.08, 95% CI 3.62-10.19, P < 0.0005). In the presence of ascites, the MELD and MELDNa scores underestimated mortality risk when the scores were less than 21. The addition of ascites to the MELDNa model substantially improved discrimination by the C-index (0.804 vs. 0.770, increase of 3.4%, 95% CI 0.2-9.9%), IDI (1.8%, P = 0.016) and NRI (15.8%, P = 0.0006).
CONCLUSION: The incorporation of radiographic ascites significantly improves upon MELDNa for predicting 1-year mortality. The presence of ascites may help identify patients at increased risk for mortality, not otherwise captured by either MELD or MELDNa.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19604177      PMCID: PMC2742706          DOI: 10.1111/j.1365-2036.2009.04096.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  18 in total

1.  Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death.

Authors:  Douglas M Heuman; Souheil G Abou-Assi; Adil Habib; Leslie M Williams; R Todd Stravitz; Arun J Sanyal; Robert A Fisher; Anastasios A Mihas
Journal:  Hepatology       Date:  2004-10       Impact factor: 17.425

2.  Serum sodium predicts mortality in patients listed for liver transplantation.

Authors:  Scott W Biggins; Harry J Rodriguez; Peter Bacchetti; Nathan M Bass; John P Roberts; Norah A Terrault
Journal:  Hepatology       Date:  2005-01       Impact factor: 17.425

3.  Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer.

Authors:  Douglas M Heuman; Anastasios Mihas
Journal:  Gastroenterology       Date:  2003-09       Impact factor: 22.682

Review 4.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

5.  Transection of the oesophagus for bleeding oesophageal varices.

Authors:  R N Pugh; I M Murray-Lyon; J L Dawson; M C Pietroni; R Williams
Journal:  Br J Surg       Date:  1973-08       Impact factor: 6.939

Review 6.  Surgery and portal hypertension.

Authors:  C G Child; J G Turcotte
Journal:  Major Probl Clin Surg       Date:  1964

7.  Survival and prognostic indicators in compensated and decompensated cirrhosis.

Authors:  G D'Amico; A Morabito; L Pagliaro; E Marubini
Journal:  Dig Dis Sci       Date:  1986-05       Impact factor: 3.199

8.  What do we mean by validating a prognostic model?

Authors:  D G Altman; P Royston
Journal:  Stat Med       Date:  2000-02-29       Impact factor: 2.373

Review 9.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

10.  Circulating levels of endothelin in cirrhosis.

Authors:  M Asbert; A Ginès; P Ginès; W Jiménez; J Clària; J Saló; V Arroyo; F Rivera; J Rodés
Journal:  Gastroenterology       Date:  1993-05       Impact factor: 22.682

View more
  10 in total

1.  Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk.

Authors:  Ma Somsouk; Rachel Kornfield; Eric Vittinghoff; John M Inadomi; Scott W Biggins
Journal:  Liver Transpl       Date:  2011-02       Impact factor: 5.799

Review 2.  Prioritization for liver transplantation.

Authors:  Evangelos Cholongitas; Giacomo Germani; Andrew K Burroughs
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-02       Impact factor: 46.802

3.  Orthotopic liver transplantation for giant liver haemangioma: A case report.

Authors:  Undine G Lange; Julian N Bucher; Markus B Schoenberg; Christian Benzing; Moritz Schmelzle; Tanja Gradistanac; Steffen Strocka; Hans-Michael Hau; Michael Bartels
Journal:  World J Transplant       Date:  2015-12-24

Review 4.  Recent advances in our understanding of hepatorenal syndrome.

Authors:  Florence Wong
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-22       Impact factor: 46.802

5.  Influence of serum sodium on MELD-based survival prediction in alcoholic hepatitis.

Authors:  Brianna E Vaa; Sumeet K Asrani; Winston Dunn; Patrick S Kamath; Vijay H Shah
Journal:  Mayo Clin Proc       Date:  2011-01       Impact factor: 7.616

6.  Model for End-Stage Liver Disease and liver cirrhosis-related complications.

Authors:  Luis Calzadilla Bertot; Eduardo Vilar Gomez; Linnet Alonso Almeida; Enrique Arus Soler; Luis Blanco Perez
Journal:  Hepatol Int       Date:  2012-10-10       Impact factor: 6.047

7.  Clinical factors predictive of insufficient liver enhancement on the hepatocyte-phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging in patients with liver cirrhosis.

Authors:  Hee Yeon Kim; Jong Young Choi; Chung-Hwa Park; Myeong Jun Song; Do Seon Song; Chang Wook Kim; Si Hyun Bae; Seung Kew Yoon; Young Joon Lee; Sung Eun Rha
Journal:  J Gastroenterol       Date:  2013-01-11       Impact factor: 7.527

Review 8.  The evolution in the prioritization for liver transplantation.

Authors:  Evangelos Cholongitas; Andrew K Burroughs
Journal:  Ann Gastroenterol       Date:  2012

9.  The Refit model for end-stage liver disease-Na is not a better predictor of mortality than the Refit model for end-stage liver disease in patients with cirrhosis and ascites.

Authors:  Jun Jae Kim; Jeong Han Kim; Ja Kyung Koo; Yun Jung Choi; Soon Young Ko; Won Hyeok Choe; So Young Kwon
Journal:  Clin Mol Hepatol       Date:  2014-03-26

10.  Prognostic Significance of Ascites and Serum Sodium in Patients with Low Meld Scores.

Authors:  Dzanela Prohic; Rusmir Mesihovic; Nenad Vanis; Amra Puhalovic
Journal:  Med Arch       Date:  2016-01-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.